Capsid-Modified rAAV3 Vectors for Liver Cancer Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant adeno-associated virus (rAAV) vectors have limited transduction efficiency and are immunogenic, making them less effective for targeted gene delivery in mammalian cells, particularly in human gene therapy applications.
Innovation Solution
Development of modified rAAV vectors with amino acid substitutions in surface-exposed residues of the viral capsid protein, such as lysine, serine, threonine, and tyrosine, to enhance transduction efficiency, stability, and reduce immunogenicity, resulting in improved viral infectivity and lower production costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type rAAV vectors are used for gene delivery, then the vectors can infect a variety of cell types, but the transduction efficiency is limited and immunogenicity occurs
Solution Approach 1:
The patent applies parameter changes by substituting specific amino acid residues (tyrosine, serine, threonine, lysine) at defined positions in the AAV capsid protein sequence with alternative amino acids. This modifies the physical-chemical properties of the capsid surface, thereby changing its interaction with host cell receptors and immune components, resulting in enhanced transduction efficiency and reduced immunogenicity
Solution Approach 2:
The patent applies local quality by making targeted amino acid substitutions at specific surface-exposed positions of the capsid protein rather than modifying the entire capsid structure. This localized modification approach allows optimization of specific interaction interfaces while preserving the overall capsid integrity and function
2Productivity
If conventional rAAV vectors are used, then production can be performed using standard methods, but production costs are higher and transduction efficiency is lower
Solution Approach 1:
The modified capsid vectors require standard transfection and production protocols, but the amino acid substitutions result in vectors that are more efficiently transduced by host cells. This reduces the amount of viral vector required per treatment, thereby lowering production costs despite using similar manufacturing processes
3Duration of action of stationary object
If standard rAAV vectors are used, then the vectors can deliver therapeutic genes, but stable expression is not achieved and repeated dosing is required
Solution Approach 1:
The amino acid substitutions in the capsid protein modify the vector's ability to enter cells and establish persistent infection. These parameter changes result in enhanced cellular uptake and nuclear delivery of the therapeutic gene, leading to stable, long-term expression that reduces or eliminates the need for repeated dosing
Data Source
AI summary
Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.